title: RQ-00202730
text: # RQ-00202730
  
  RQ-00202730 is a benzimidazole derived drug that acts as a potent and highly selective agonist for the $CB_2$ cannabinoid receptor, with a $K_i$ value of 19nM at $CB_2$ and more than 4000x selectivity over $CB_1,$ though it also shows some activity as an antagonist of the unrelated $5-HT_{2B}$ serotonin receptor. It has analgesic and antiinflammatory effects in animal studies, and was developed for the treatment of irritable bowel syndrome, but was ultimately discontinued from development following disappointing results in Phase II clinical trials.
  
  